Early Study Finds New Lymphoma Drug Effective

According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.